Key result
The novel polymeric TAVR valve passed 400 million cycles without failure and demonstrated significantly lower calcium and phosphorus deposition compared to tissue valves.
Why the study?
Current clinically used tissue TAVR valves suffer from limited durability, which hampers the expansion of TAVR to younger and lower-risk patients.
Population
Novel polymeric TAVR valve (PolyNova valve) and clinically used tissue valves
Comparison
PolyNova polymeric TAVR valve vs clinically used tissue valves
Design
In vitro durability and stability study
Authors
Loading...
Polymeric TAVR valves demonstrate in vitro durability and hemocompatibility; leaves open clinical translation to younger patients.
A novel polymeric TAVR valve demonstrated excellent in vitro durability and significantly reduced calcification compared to standard tissue valves, suggesting potential as a longer-lasting alternative for younger patients.
Rotman et al. (2019) studied Severe aortic stenosis. PolyNova valve (polymeric TAVR valve) vs. Clinically used tissue valves was evaluated on Durability, calcification susceptibility, and crimping stability. The novel polymeric TAVR valve passed 400 million cycles without failure and demonstrated significantly lower calcium and phosphorus deposition compared to tissue valves.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: